Project Grant R01HL171199
Award Date
7/29/24
Completion Date
6/30/29
Dollars Obligated
$828K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), aims to develop and evaluate deep generative models using computed tomography (CT) images to predict acute respiratory distress syndrome (ARDS) progression and treatment responses. The project, funded through the Cardiovascular Diseases Research (CFDA 93.837) program, will leverage artificial intelligence techniques such as generative adversarial networks (GANs)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $322,480 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of endothelial sphingosine-1-phosphate receptor 1 (S1PR1) in promoting lung repair after viral infections that lead to acute respiratory distress syndrome (ARDS). The research aims to define the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $122,788 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal models of idiopathic pulmonary fibrosis (IPF). The goal is to use dynamic...
This Project Grant award of $604,115 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support an observational study to evaluate the use of advanced imaging technologies, including PET and dynamic contrast-enhanced MRI, to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease. The study aims to determine if these innovative imaging...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,220,472 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on using B cells to treat acute respiratory distress syndrome (ARDS) and associated neurological complications. The project aims to administer naive B cells to ameliorate inflammatory responses and promote tissue protection in a...
This federal Project Grant award of $268,500.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate a quantitative marker of pulmonary microvascular injury and explore its correlation with the progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The key products and services to be delivered include: Extending the validation of an AI-based algorithm for...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,160,157 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Liberandum Technologies, Inc. in San Francisco, CA. The goal of this Phase I Small Business Innovation Research (SBIR) project is to develop and test a bidirectional synchronous flow-controlled ventilation system to improve oxygenation and ventilation in patients with acute respiratory distress syndrome (ARDS). The ventilation system aims to provide gentle...
This federal Project Grant award of $153,099 from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), will support research to address important gaps in the treatment of Acute Respiratory Distress Syndrome (ARDS). The primary awardee, the Massachusetts Institute of Technology (MIT), will utilize large observational datasets, including the MIMIC-IV and eICU databases, to conduct target trial emulations and apply causal...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) provides $480,990 to the University of Illinois to investigate the role of aerocytes, a specialized capillary endothelial cell population, in regulating alveolar epithelial regeneration following lung injury. The research aims to establish aerocytes as central regulators of alveolar regeneration, with a focus on the signaling...
This $873,736 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to validate the use of the end tidal alveolar dead space fraction (AVDSF) as a risk stratification marker for mortality in pediatric acute respiratory distress syndrome (ARDS). The research aims to determine if AVDSF can identify patient subgroups that may benefit from inhaled nitric oxide (INO) therapy, and explore...